for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recipharm AB (publ)

RECIb.ST

Latest Trade

117.80SEK

Change

3.80(+3.33%)

Volume

195,632

Today's Range

114.60

 - 

117.80

52 Week Range

82.50

 - 

166.90

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
114.00
Open
114.60
Volume
195,632
3M AVG Volume
6.99
Today's High
117.80
Today's Low
114.60
52 Week High
166.90
52 Week Low
82.50
Shares Out (MIL)
68.15
Market Cap (MIL)
5,991.04
Forward P/E
38.35
Dividend (Yield %)
--

Next Event

Recipharm AB (publ) at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

The Board Of Directors Of Recipharm Resolves On A Rights Issue

Recipharm Secures Supply Of Drug Substance And Commences Manufacture Of Chloroquine Phosphate

Recipharm Q1 EBITDA Up At SEK 431 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recipharm AB (publ)

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among others; and Development and Technology, offering clinical supply, product development, formulation, analytical development, stability studies, packaging development and raw material selection, as well as regulatory advice. It is also engaged in the development of own product portfolio. The Company targets two customer segments: large pharmaceutical companies, outsourcing part of their production; and small and medium-sized enterprises, outsourcing manufacturing and development services. Recipharm publ AB operates as a parent entity of the Recipharm Group, comprising approximately 15 subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

Box 603, Drottninggatan 29

101 32

Sweden

+46.8.6025200

https://www.recipharm.com/

Executive Leadership

Lars Backsell

Chairman of the Board

Thomas Eldered

Chief Executive Officer, Director

Tobias Hagglov

Chief Financial Officer

Kjell Johansson

President, Manufacturing Services Europe

Bernard Pluta

President - Development Services

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2017

5.3K

2018

6.4K

2019

7.5K

2020(E)

11.3K
EPS (SEK)

2017

1.100

2018

2.730

2019

5.390

2020(E)

5.655
Price To Earnings (TTM)
380.39
Price To Sales (TTM)
0.73
Price To Book (MRQ)
1.38
Price To Cash Flow (TTM)
6.73
Total Debt To Equity (MRQ)
242.74
LT Debt To Equity (MRQ)
240.45
Return on Investment (TTM)
0.20
Return on Equity (TTM)
0.18

Latest News

Latest News

BRIEF-Recipharm Q1 EBITDA Up At SEK 250 Million

* Q1 NET SALES SEK 1.51 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation

* RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES

BRIEF-Recipharm CFO Resigns

* HENRIK STENQVIST WILL SERVE AS CFO UNTIL LATER IN SPRING.

BRIEF-Recipharm Q4 EBITDA At SEK 226 Million

* Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

BRIEF-Recipharm Buys Remaining Shares In Nitin Lifesciences

* RECIPHARM ACQUIRES REMAINING SHARES IN NITIN LIFESCIENCES LTD

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)

BRIEF-Recipharm equips a further three facilities for U.S serialisation

* RECIPHARM EQUIPS A FURTHER THREE FACILITIES FOR US SERIALISATION Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 EBITDA SEK 103 MILLION VERSUS SEK 144 MILLION YEAR AGO

BRIEF-Recipharm to end operations in two facilities in Sweden

* TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 NET SALES SEK 1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO

BRIEF-Recipharm starts cooperation with Roche

* RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN

BRIEF-Recipharm, Kancera cooperate to manufacture clinical trial supply

* RECIPHARM AND KANCERA COLLABORATE TO MANUFACTURE CLINICAL TRIAL SUPPLY

BRIEF-Recipharm Q2 EBITDA SEK 242 million

* Q2 NET SALES SEK 1.40 BILLION VERSUS SEK 1.24 BILLION YEAR AGO

BRIEF-Recipharm and Lidds establish industrial manufacturing capabilities

* RECIPHARM AND LIDDS ESTABLISH INDUSTRIAL MANUFACTURING CAPABILITIES FOR A NOVEL PROSTATE CANCER PRODUCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up